FDA 505(b)(2) Policy Affirmed; Any Changes Will Be Too Late For Norvasc

FDA will reconsider whether approval of new salt formulations under the Sec. 505(b)(2) process is appropriate, but any changes will not prevent approval of a pending competitor to Pfizer's antihypertensive Norvasc

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet